Dual inhibition of Src and MEK decreases the growth of human ovarian cancer cells

Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors, saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of apoptosis and cell cycle arrest in vitro and tumor inhibition in xenografts. There are three biological replicates per experimental sample.